Mathewos Tessema1, Michael R Rossi2, Maria A Picchi3, Christin M Yingling3, Yong Lin3, Suresh S Ramalingam4, Steven A Belinsky5. 1. Lung Cancer Program, Lovelace Respiratory Research Institute, Albuquerque, NM, USA. Electronic address: mtessema@LRRI.org. 2. Departments of Pathology and Laboratory Medicine, Radiation Oncology, USA. 3. Lung Cancer Program, Lovelace Respiratory Research Institute, Albuquerque, NM, USA. 4. Hematology and Oncology, Emory University School of Medicine, Winship Cancer Institute, Atlanta, GA, USA. 5. Lung Cancer Program, Lovelace Respiratory Research Institute, Albuquerque, NM, USA. Electronic address: sbelinsk@LRRI.org.
Abstract
OBJECTIVES: Lung adenocarcinoma in never-smokers accounts for 15-20% of all lung cancer. Although targetable mutations are more prevalent in these tumors, the biological and clinical importance of coexisting and/or mutually exclusive abnormalities is just emerging. This study evaluates the relationships between common genetic and epigenetic aberrations in these tumors. MATERIALS AND METHODS: Next-generation sequencing was employed to screen 20 commonly mutated cancer-driver genes in 112 lung adenocarcinomas from never-smokers. The relationship of these mutations with cancer-related methylation of 59 genes, and geographical/ethnic differences in the prevalence for mutations compared to multiple East Asian never-smoker lung adenocarcinoma cohorts was studied. RESULTS: The most common driver mutation detected in 40% (45/112) of the tumors was EGFR, followed by TP53 (18%), SETD2 (11%), and SMARCA4 (11%). Over 72% (81/112) of the cases have mutation of at least one driver gene. While 30% (34/112) of the tumors have co-mutations of two or more genes, 42% (47/112) have only one driver gene mutation. Differences in the prevalence for some of these mutations were seen between adenocarcinomas in East Asian versus US (mainly Caucasian) never-smokers including a significantly lower rate of EGFR mutation among the US patients. Interestingly, aberrant methylation of multiple cancer-related genes was significantly associated with EGFR wildtype tumors. Among 15 differentially methylated genes by EGFR mutation, 14 were more commonly methylated in EGFR wildtype compared to mutant tumors. These findings were independently validated using publicly available data. CONCLUSION: Most lung adenocarcinomas from never-smokers harbor targetable mutation/co-mutations. In the absence of EGFR mutation that drives 40% of these tumors, EGFR wildtype tumors appear to develop by acquiring aberrant promoter methylation that silences tumor-suppressor genes.
OBJECTIVES:Lung adenocarcinoma in never-smokers accounts for 15-20% of all lung cancer. Although targetable mutations are more prevalent in these tumors, the biological and clinical importance of coexisting and/or mutually exclusive abnormalities is just emerging. This study evaluates the relationships between common genetic and epigenetic aberrations in these tumors. MATERIALS AND METHODS: Next-generation sequencing was employed to screen 20 commonly mutated cancer-driver genes in 112 lung adenocarcinomas from never-smokers. The relationship of these mutations with cancer-related methylation of 59 genes, and geographical/ethnic differences in the prevalence for mutations compared to multiple East Asian never-smoker lung adenocarcinoma cohorts was studied. RESULTS: The most common driver mutation detected in 40% (45/112) of the tumors was EGFR, followed by TP53 (18%), SETD2 (11%), and SMARCA4 (11%). Over 72% (81/112) of the cases have mutation of at least one driver gene. While 30% (34/112) of the tumors have co-mutations of two or more genes, 42% (47/112) have only one driver gene mutation. Differences in the prevalence for some of these mutations were seen between adenocarcinomas in East Asian versus US (mainly Caucasian) never-smokers including a significantly lower rate of EGFR mutation among the US patients. Interestingly, aberrant methylation of multiple cancer-related genes was significantly associated with EGFRwildtype tumors. Among 15 differentially methylated genes by EGFR mutation, 14 were more commonly methylated in EGFR wildtype compared to mutant tumors. These findings were independently validated using publicly available data. CONCLUSION: Most lung adenocarcinomas from never-smokers harbor targetable mutation/co-mutations. In the absence of EGFR mutation that drives 40% of these tumors, EGFRwildtype tumors appear to develop by acquiring aberrant promoter methylation that silences tumor-suppressor genes.
Authors: Robert Pirker; Felix J F Herth; Keith M Kerr; Martin Filipits; Miquel Taron; David Gandara; Fred R Hirsch; Dominique Grunenwald; Helmut Popper; Egbert Smit; Manfred Dietel; Antonio Marchetti; Christian Manegold; Peter Schirmacher; Michael Thomas; Rafael Rosell; Federico Cappuzzo; Rolf Stahel Journal: J Thorac Oncol Date: 2010-10 Impact factor: 15.609
Authors: Alexander Drilon; Salvatore Siena; Sai-Hong Ignatius Ou; Manish Patel; Myung Ju Ahn; Jeeyun Lee; Todd M Bauer; Anna F Farago; Jennifer J Wheler; Stephen V Liu; Robert Doebele; Laura Giannetta; Giulio Cerea; Giovanna Marrapese; Michele Schirru; Alessio Amatu; Katia Bencardino; Laura Palmeri; Andrea Sartore-Bianchi; Angelo Vanzulli; Sara Cresta; Silvia Damian; Matteo Duca; Elena Ardini; Gang Li; Jason Christiansen; Karey Kowalski; Ann D Johnson; Rupal Patel; David Luo; Edna Chow-Maneval; Zachary Hornby; Pratik S Multani; Alice T Shaw; Filippo G De Braud Journal: Cancer Discov Date: 2017-02-09 Impact factor: 39.397
Authors: Heather A Wakelee; Ellen T Chang; Scarlett L Gomez; Theresa H Keegan; Diane Feskanich; Christina A Clarke; Lars Holmberg; Lee C Yong; Laurence N Kolonel; Michael K Gould; Dee W West Journal: J Clin Oncol Date: 2007-02-10 Impact factor: 44.544
Authors: Kevin E Fisher; Linsheng Zhang; Jason Wang; Geoffrey H Smith; Scott Newman; Thomas M Schneider; Rathi N Pillai; Ragini R Kudchadkar; Taofeek K Owonikoko; Suresh S Ramalingam; David H Lawson; Keith A Delman; Bassel F El-Rayes; Malania M Wilson; H Clifford Sullivan; Annie S Morrison; Serdar Balci; N Volkan Adsay; Anthony A Gal; Gabriel L Sica; Debra F Saxe; Karen P Mann; Charles E Hill; Fadlo R Khuri; Michael R Rossi Journal: J Mol Diagn Date: 2016-01-20 Impact factor: 5.568
Authors: Y U Dong; Weihong Ren; Jun Qi; B O Jin; Ying Li; Huiqing Tao; Ren Xu; Yanqing Li; Qinxian Zhang; Baohui Han Journal: Oncol Lett Date: 2016-02-17 Impact factor: 2.967